Guilherme Barroso Langoni De Freitas

Guilherme Barroso Langoni De Freitas

Auto-generated profile, based on publicly available information

Guilherme Barroso Langoni De Freitas

Postgraduate Program in Pharmacology, Federal University of Piauí, Ministro Petrônio Portella University Campus,Piauí, Brazil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in F1000Research
Verified
Journal Article
Open access
PDF file
EGElizama de Gregorio
Elizama de Gregorio
DMDayanna Hartmann Cambruzzi Mendes
Dayanna Hartmann Cambruzzi Mendes
LPLuan Henrique Patrzyk
Luan Henrique Patrzyk
LFLuana Felski
Luana Felski
GFGuilherme Barroso Langoni de Freita
Guilherme Barroso Langoni de Freita
WSWeber Cláudio Francisco Nunes da Silva
Weber Cláudio Francisco Nunes da Silva
Introduction: Dementia is a common health problem in elderly people, Alzheimer disease (AD) being the most prevalent. AD can be considered as a cause of death and must be registered on the death certificate of the patients. However, most of the time, the main cause of death registered is not related to AD, but as an underlying or contributing cause. For example, individuals who have AD and die from myocardium infarction. This study aimed to analyze if nutritional status was associated with survival and mortality for AD, and if AD was reported as actual cause of death on the death certificate Methods: The study was carried out as a cross-sectional study with elderly citizens of the community registered in the National Health System (SUS), with cognitive, nutritional, biochemical and hematological evaluations of 30 AD patients in Guarapuava, Paraná state, Brazil. Results: Significant differences were not observed between live and dead patients when evaluated considering the methods applied. Only 22% of the death certificates stated death due to AD. The patient’s cause of death showed a strong relation to respiratory issues; potential explanations based on immunological, biochemical and comorbidity were not confirmed on this study. Conclusions: AD was not declared as the cause of death in the majority of certificates, contributing to the underreporting and reducing the information of death due to AD in the country.

29 November 2017 in F1000Research
Verified
Journal Article
Open access
PDF file
FVFelipe Nathanael Coelho Vaz
Felipe Nathanael Coelho Vaz
LTLuana Bortoluzzi Trombim
Luana Bortoluzzi Trombim
GFGuilherme Barroso L. de Freitas
Guilherme Barroso L. de Freitas
MHMaria Vaitsa Loch Haskel
Maria Vaitsa Loch Haskel
GSGiovana dos Santos
Giovana dos Santos
Juliana Sartori BoniniJuliana Sartori Bonini
Juliana Sartori Bonini
Background: Elderly patients frequently have concomitant diseases, triggering the necessity of utilizing several different medications, which can cause adverse events associated with therapy, called polypharmacy. This study aimed to evaluate the main concomitant diseases with Alzheimer's disease (AD) and discuss possible interactions between drugs utilized to treat dementia and its comorbidities, and indicate safe medicines for patients with AD. Methods: 41 individuals with AD who withdraw medicines for dementia from the Brazilian public health system (SUS) participated in this study. Data collection was performed using three questionnaires: 1) Clinical Dementia Rating, to verify disease stage; 2) Mini–mental state examination, to measure cognitive impairment; and 3) Sociodemographic analysis, to evaluate concomitant diseases, utilized drugs, drug-drug interactions, among other demographic variables. Statistical analyses were performed using SPSS and data was presented as relative frequency. Results: The results of this study showed that the most frequent concomitant diseases with AD are: systemic arterial hypertension, depression, diabetes mellitus, and hypercholesterolemia. Polypharmacy was observed in 95.12% of patients. The pharmacologic classes that presented interactions with AD medications were anxiolytics, antidepressants, antipsychotics, antihypertensives, and antidiabetics. Conclusion: In the present study, polypharmacy in patients with AD and other concomitant diseases has been characterized. The average number of drugs that these patients ingested was seven per day, and this leads to drug interactions, which are potentially damaging to the body. Consequently, we have tried to reduce these interactions, by suggesting drugs that are safer, for example furosemide instead of amlodipine to treat hypertension.

17 May 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
AMAna Grazielly Rodrigues de Macedo
Ana Grazielly Rodrigues de Macedo
GCGabriela Dantas Carvalho
Gabriela Dantas Carvalho
GGGuilherme Pertinni de Morais Gouveia
Guilherme Pertinni de Morais Gouveia
YAYaranara Linhares Aragão
Yaranara Linhares Aragão
SGSamara Sousa Vasconcelos Gouveia
Samara Sousa Vasconcelos Gouveia
RCRayssa Maria de Araujo Carvalho
Rayssa Maria de Araujo Carvalho
Objetiva-se avaliar o conhecimento e as condutas adotadas pelos acadêmicos de odontologia acerca do atendimento de pacientes soropositivo. Trata-se de um estudo transversal, quantitativo, realizado entre junho a dezembro de 2020. O trabalho foi aprovado pelo Comitê de Ética do Centro Universitário UNIFACID sob o número de parecer 075913/2020. Os dados foram coletados por meio da aplicação de um questionário aos acadêmicos de odontologia do 6° ao 10° período de um Centro Universitário de Teresina. Os dados foram tabulados no Excel® e analisados de forma descritiva. Participaram 97 alunos, predominantemente feminino (73,2%, n=71), com idade entre 20-29 anos (93,8%, n=91), que fazem o uso da máscara e touca (79,4%, n=77), avental cirúrgico (86,6%, n=84) e luvas (82,5%, n=80). A maioria (85,6%, n=83) confirmou atender os pacientes soro positivo, mesmo mostrando preocupação quanto ao risco de infecção (96,9%, n=94). Uma parte (18,6%; n=18) acusou ter sofrido lesão com material perfurocortante, contudo, apenas 8,2% (n=8) realizaram a testagem anti-HIV. Quanto aos cuidados adotados: 94,8% (n=92) conduziriam higienizando com água e sabão e o uso de antissépticos (81,4%, n= 79). Não houve consenso quanto ao direito de negar o atendimento, valor cobrado e ambiente indicado ao atendimento, porém todos se mostram seguros e preparados ao manejo do paciente soro positivo, com insegurança aos procedimentos cruentos (59,8%, n=58) e diagnóstico das lesões bucais (51,5%, n=50). Os acadêmicos têm preocupação quanto aos riscos, porém mostram ter conhecimento científico e técnico sobre a doença, o que faz com que mostrem segurança no atendimento dos pacientes soro positivo.

8 January 2026 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
JGJosé Gabriel Fontenele Gomes
José Gabriel Fontenele Gomes
Bruno Barbosa SousaBruno Barbosa Sousa
Bruno Barbosa Sousa
BABoris Timah Acha
Boris Timah Acha
NLNeirigelson Ferreira de Barros Leite
Neirigelson Ferreira de Barros Leite
JLJoão Pedro Alves Damaceno Do Lago
João Pedro Alves Damaceno Do Lago
GFGuilherme Barroso Langoni De Freitas
Guilherme Barroso Langoni De Freitas
Introduction: Dihydromyricetin (DMY) presents itself as a promising therapeutic candidate due to its inhibitory effects on various receptor tyrosine kinases, prompting an investigation of its structural characteristics, molecular interactions, and biological activity across the FGFR, HER, PDGFR, and VEGFR families. Methods: Protein sequences and structures for FGFR1/2, HER2/3, PDGFRA/B, and VEGFR1/2 were retrieved from UniProt/PDB. DMY and reference inhibitors were docked to each kinase using AutoDock Vina. Anti-angiogenic activity was measured by HET-CAM assay with vessel metrics quantified via IKOSA CAM. MTT determined cytotoxicity (IC₅₀) and tumor-selectivity index in 4T1 and L929 cells; data (mean ± SEM) were analyzed by one-way ANOVA with Tukey’s test (p < 0.005). Results: DMY exhibited docking scores comparable to established inhibitors, achieved over 45 % inhibition of neovascularization in the HET-CAM assay at nanomolar concentrations, displayed a tumor-selectivity index of less than one in 4T1 versus L929 cells (mirroring many clinical chemotherapeutics), and, notably, coadministration with doxorubicin reduced in vitro cardiotoxicity markers. Discussion: The high-affinity, multi-kinase binding profile and significant anti-angiogenic efficacy underscore DMY’s multifunctional potential, while its tumor-selectivity index aligns with accepted therapeutic risk–benefit balances and its cardioprotective effect suggests a way to mitigate anthracycline toxicity. Conclusion: These findings indicate that DMY is a multifunctional agent exhibiting both antiangiogenic and cytotoxic properties, warranting further preclinical and clinical investigation.